Clinical Activity Of Cirmtuzumab, An Anti-Ror1 Antibody, In Combination With Ibrutinib: Interim Results Of A Phase Ib/Ii Study In Mantle Cell Lymphoma (Mcl) Or Chronic Lymphocytic Leukemia (Cll).
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要